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Background: Atherosclerosis is an inflammatory process of the arterial walls and is initiated by endothelial
dysfunction accompanied by an imbalance in the production of reactive oxygen species (ROS) and nitric oxide
(NO). Sildenafil, a selective phosphodiesterase-5 (PDE5) inhibitor used for erectile dysfunction, exerts its
cardiovascular effects by enhancing the effects of NO. The aim of this study was to investigate the influence of
sildenafil on endothelial function and atherosclerosis progression in apolipoprotein E knockout (apoE−/−) mice.
Methods: ApoE−/− mice treated with sildenafil (ViagraW, 40 mg/kg/day, for 3 weeks, by oral gavage) were
compared to the untreated apoE−/− and the wild-type (WT) mice.
Aortic rings were used to evaluate the relaxation responses to acetylcholine (ACh) in all of the groups. In a separate
set of experiments, the roles of NO and ROS in the relaxation response to ACh were evaluated by incubating the
aortic rings with L-NAME (NO synthase inhibitor) or apocynin (NADPH oxidase inhibitor). In addition, the
atherosclerotic lesions were quantified and superoxide production was assessed.
Results: Sildenafil restored the vasodilator response to acetylcholine (ACh) in the aortic rings of the apoE−/− mice.
Treatment with L-NAME abolished the vasodilator responses to ACh in all three groups of mice and revealed an
augmented participation of NO in the endothelium-dependent vasodilation in the sildenafil-treated animals. The
normalized endothelial function in sildenafil-treated apoE−/− mice was unaffected by apocynin highlighting the low
levels of ROS production in these animals. Moreover, morphological analysis showed that sildenafil treatment
caused approximately a 40% decrease in plaque deposition in the aorta.
Conclusion: This is the first study demonstrating the beneficial effects of chronic treatment with sildenafil on
endothelial dysfunction and atherosclerosis in a model of spontaneous hypercholesterolemia. These data indicate
that the main mechanism of the beneficial effect of sildenafil on the endothelial function appears to involve an
enhancement of the NO pathway along with a reduction in oxidative stress.
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Atherosclerosis, which can be defined as a chronic and
progressive disease characterized by an inflammatory re-
sponse of the arterial wall, is still a leading cause of death,
mainly in the Western world [1,2]. The development of
atherosclerotic plaques is influenced by oxidative stress,
an imbalance between the accumulation of reactive* Correspondence: evasquez@pq.cnpq.br
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reproduction in any medium, provided the oroxygen species (ROS) mainly produced by NADPH oxi-
dase and limited antioxidant defenses; this imbalance
compromises nitric oxide (NO) availability and leads to
endothelial dysfunction [3,4]. Early studies suggest that
the correction of endothelial dysfunction results in a bet-
ter prognosis [5], supporting the need for drugs to im-
prove endothelial function and to reduce the progression
of atherosclerosis [6].
Sildenafil, which has largely been used for erectile dys-
function and pulmonary hypertension [7], is being used to
enhance in vivo NO signaling in other vascular diseases asLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cellular second messenger of NO (cGMP) by inhibition of
phosphodiesterase-5 (PDE5). Sildenafil was recently shown
to improve endothelial function in coronary arterial disease
as well as in diabetes and to reduce oxidative stress in
many tissues [8-11]. However, the drug has not yet been
tested in experimental models of atherosclerosis.
The apolipoprotein E knockout (apoE−/−) mouse devel-
oped two decades ago [12,13], exhibits spontaneous hyper-
cholesterolemia, accompanied by endothelial dysfunction
similar to that observed in humans [4,14,15]. Therefore,
the apoE−/− mouse seems to be a suitable genetic model
to test new therapeutic approaches for the treatment of
vascular diseases observed in dyslipidemias [16].
The aim of the present study was to test the hypoth-
esis that chronic sildenafil treatment could revert or re-
duce the endothelial dysfunction and the progression of
atherosclerosis observed in large vessels of apoE−/− mice.
Our data show that this drug was able to restore the
endothelial function in the aorta of apoE−/− mice, pri-
marily by enhancing the activation of the NO pathway
and by decreasing ROS production.
Materials and methods
Animals
Experiments were conducted in adult (18-week-old) male
apoE−/− mice, which have a C57BL/6J genetic background,
and on C57BL/6J wild-type (WT) mice, bred and main-
tained in the animal care facility at the Laboratory of
Transgenes in the Health Sciences Center at the Federal
University of Espirito Santo, Brazil. Mice were housed in
individual plastic cages with a controlled temperature
(22-23°C) and humidity (60%) and were exposed to a
12:12-h light–dark cycle. All experimental procedures
were performed in accordance with the guidelines for the
care and handling of laboratory animals as recommended
by the National Institutes of Health (NIH), and study
protocols were previously approved by the Institutional
Animal Care Committee (CEUA-Emescam, Protocol
# 007/2010).
To accelerate and aggravate the spontaneous hyperlip-
idemia and progression of endothelial dysfunction and
atherosclerosis in apoE−/− mice, the animals were fed a
Western-type diet for 10 weeks, starting at 8 weeks of
age (AIN93G modified diet, Rhoster, Brazil). After
7 weeks (15-week-old), the mice were divided into three
different groups: (a) apoE−/− mice treated with the PDE5
inhibitor sildenafil (ViagraW, 40 mg/kg/day, for 3 weeks,
by oral gavage), (b) apoE−/− mice treated with the vehicle
and (c) WT control mice, treated with the vehicle.
Measurement of plasma lipids
Blood samples were obtained by puncturing the right ven-
tricle of the animals euthanized with an overdose ofthiopental sodium anesthetic. The blood was immediately
transferred to a tube containing heparin and centrifuged
at 3000 RPM for 10 min. Plasma was separated immedi-
ately and kept at −20°C until assayed. Total plasma cho-
lesterol, high density lipoproteins (HDL), low density
lipoproteins (LDL) and triglycerides were determined using
commercial colorimetric assay kits (Bioclin, Belo Horizonte,
Brazil). Very low density lipoproteins (VLDL) and inter-
mediate density lipoproteins (IDL) were estimated by sub-
tracting HDL and LDL from total serum cholesterol.
Vascular function
After the treatment, animals were anesthetized with a
sodium thiopental injection (200 mg/kg, i.p.), blood sam-
ples were collected and the thoracic aorta was removed
and immediately placed in modified Krebs buffer of the
following composition (in mM): NaCl 115, KCl 4.7,
CaCl2•2H2O 2.5, MgSO4•7H2O 1.2, KH2PO4 1.2,
NaHCO3 25, EDTA 0.01 and glucose 11.1. Loose con-
nective tissue in the adventitia was carefully removed to
avoid damage, and the vessel was cut into rings (3 to
4 mm thick). The aortic rings were then mounted on
stainless steel triangles, suspended in vertical organ
baths containing 5 ml Krebs solution, maintained at a
resting tension of 0.5 g at 37°C, pH 7.4 and continuously
gassed with a mixture of 95% O2 and 5% CO2. The rings
were connected to force transducers to measure isomet-
ric tension through a computerized acquisition system
(MP100, Biopac Systems Inc., Santa Barbara, USA).
After a 60-min equilibration period, aortic rings were
exposed to KCl (125 mM) to assess their maximal tension.
The endothelial function was then verified by acetylcholine
(ACh)-induced relaxation (10 μM) after pre-contraction
with phenylephrine (PE, 10 μM); the endothelium was
considered functional when the relaxation was greater
than 50%. After a washout period of 30 minutes,
endothelium-dependent relaxation responses were tested
by concentration-response curves to cumulative concen-
trations of ACh (100 pM – 30 μM).
In a separate set of experiments, the role of NO and
ROS in the relaxation response to ACh were evaluated
by incubation of the aortic rings with the non-specific
NO synthase (NOS) inhibitor N(G)-nitro-L-arginine me-
thyl ester (L-NAME, 100 μM), or the NADPH oxidase
inhibitor apocynin (300 μM) that were added to the ves-
sel bath 20 minutes prior to assessing the concentration-
response curves. The area under the curve (AUC) for
each of the responses of the aortic rings to ACh in the
presence or absence of L-NAME was calculated, and
these results were expressed in arbitrary units.
Quantification of the atherosclerotic lesion
In another set of animals, the mice were euthanized with
a sodium thiopental overdose (200 mg/kg, i.p.), and the
Table 1 Lipid profiles of vehicle- and sildenafil-treated
apolipoprotein E-deficient (apoE−/−) mice fed a
Western-type diet and wild-type control (WT)
Parameter WT apoE−/−
Vehicle Sildenafil
Triglycerides (mg/dL) 61 ± 9 241 ± 36** 196 ± 46*
Total plasma cholesterol (mg/dL) 94 ± 5 1308 ± 145** 1310 ± 223**
LDL (mg/dL) 23 ± 6 180 ± 29** 190 ± 48**
HDL (mg/dL) 58 ± 4 15 ± 4** 10 ± 1**
VLDL + IDL (mg/dL) 26 ± 5 1115 ± 28** 1111 ± 48**
Values are mean ± SEM of 5–10 mice per group. *p < 0.05 and **p < 0.01 vs.
WT (one-way ANOVA).
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buffered saline (PBS, pH 7.4), followed by a 4% formal-
dehyde solution in PBS at a pressure of 100 mm Hg.
The aortic root and a portion of the ascendant aorta were
removed, placed in PBS, dissected free from fat and adher-
ing perivascular tissue, embedded in OCT compound and
cross-sectioned on a cryostat (Jung CM1800; Leica,
Wetzlar, Germany) at a thickness of 7 μm. For each ani-
mal, aorta cross-sections were mounted on gelatin-coated
slides and stained with Oil-Red-O (Sigma-Aldrich, St.
Louis, MO, USA). Atherosclerotic lesions were quantified
using a microscope (Olympus AX70, Olympus, Center
Valley, PA, USA) interfaced with a video camera (VKC150,
Hitachi, Tokyo, Japan) and an image analysis system
(Image J, Public Domain). The lesion area per mouse was
calculated by an investigator who was blinded to the ex-
perimental protocol and was expressed as a percentage of
the lumen occupied by the atherosclerotic plaque.
Detection of superoxide production
Unfixed frozen sections from the aorta were cut into
7-μm-thick sections and mounted on gelatin coated glass
slides. Samples were incubated with the oxidative fluores-
cent dye dihydroethidium (DHE, 2 μmol/L) in a modified
Krebs's solution (containing 20 mM HEPES), in a light-
protected humidified chamber at 37°C for 30 min, to detect
superoxide. The intensity of fluorescence was quantified in
the tissue sections using a microscope (Nikon Eclipse TI,
Nikon Instruments Inc., Melville, NY, USA) by an investi-
gator blinded to the experimental protocol.
Statistical analysis
Values were expressed as the means ± S.E.M. Relaxation
responses to ACh and SNP were expressed as the percent-
age of dilation relative to the maximal pre-contraction
level. For each concentration-response curve, the max-
imum effect (Rmax) and the log of the concentration of
agonist that produced half of Rmax (log EC50) were calcu-
lated using nonlinear regression analysis. The sensitivities
of the agonists were expressed as pEC50 (−log EC50).
Statistical comparisons between the different groups were
performed by one-way or two-way analysis of variance
(ANOVA) followed by Bonferroni’s post hoc test. The stat-
istical analyses were performed using Prism software
(Prism 5, GraphPad Software, Inc., San Diego, CA, USA).
A value of p < 0.05 was regarded as statistically significant.
Results
Table 1 summarizes the results of plasma lipid profile of
the three groups of animals. As expected, the apoE−/−
vehicle group which received a Western type diet for
10 weeks, showed a significant increase in triglycerides
(4-fold) along with a marked increase in total plasma
cholesterol (14-fold) and VLDL + IDL (42-fold), whencompared to the WT mice. On the other hand, HDL
was significantly decreased (4-fold) in the apoE−/− mice
compared to the WT mice. Sildenafil treatment did not
change the profile in apoE−/− animals.
The maximal vascular response (Rmax) and sensitivity
(pEC50) to ACh were significantly decreased in the aortas
of untreated apoE−/− animals, compared to those of the
WT mice (Table 2, Figure 1A). This impaired ACh-induced
relaxation response in the apoE−/− mice was completely
restored on sildenafil treatment to values similar to those
observed in the WT mice (Table 2, Figure 1B).
To evaluate the participation of NO in endothelium-
dependent vasodilator responses, aortic rings were incu-
bated with L-NAME prior to ACh concentration-response
curves. In all groups, L-NAME did block the vasodilator
response elicited by ACh (Table 2, Figures 2A, 2B, 2C).
Moreover, analysis of the difference of the AUC revealed
that the participation of NO in the relaxation response to
ACh was significantly reduced in the untreated apoE−/−
mice when compared to the WT mice (58 ± 17 vs. 230 ±
11, p < 0.01). Sildenafil treatment recovered the normal
ACh-induced relaxation in apoE−/− mice when compared
to untreated apoE−/− mice (233 ± 10, p < 0.01, Figure 2D).
The participation of ROS in the relaxation response to
ACh was assessed by incubation of the aortic rings with
apocynin. We did not observe significant changes in the
vascular reactivity after apocynin blockage in the WT
animals, indicating that ROS may not participate in
these responses (Table 2, Figure 3A). However, apocynin
significantly increased maximal relaxing response and
sensitivity to ACh in aortas of untreated apoE−/− mice
(Table 2, Figure 3B). In apoE−/− mice treated with silde-
nafil, the ACh-induced vasorelaxation in the presence of
apocynin was similar to that observed in WT mice
(Table 2, Figure 3C).
Figure 4 summarizes the results of histological analyses
of aorta from the three groups of animals. ApoE−/− mice
showed a significant plaque deposition in the aortic root
when compared to WTanimals (37.7 ± 3.4% vs. 0.0 ± 0.0%,
p < 0.01). Sildenafil treatment in the apoE−/− animals
Table 2 Effect of L-NAME and apocynin on the efficacy of
and sensitivity to acetylcholine in isolated aortic rings from
wild-type control (WT) mice and from vehicle- and
sildenafil-treated apolipoprotein E-deficient (apoE−/−) mice
Curve parameter WT apoE−/−
Vehicle Sildenafil
Acetylcholine
Rmax (%) 87 ± 3.6 66 ± 9.7* 95 ± 3.1
#
pEC50 7.3 ± 0.1 6.1 ± 0.1** 7.2 ± 0.3
##
Acetylcholine + L-NAME
Rmax (%) 11 ± 2.0
§§ 18 ± 4.4§§ 12 ± 2.8§§
pEC50 8.7 ± 0.5
§ 8.5 ± 0.2§§ 7.3 ± 1.1
Acetylcholine + apocynin
Rmax (%) 84 ± 5.2 101 ± 4.6
§§ 94 ± 3.7
pEC50 7.3 ± 0.2 7.3 ± 0.2
§§ 7.2 ± 0.2
Rmax, maximal response (efficacy). pEC50, the negative logarithm of the
concentration required to produce 50% of the Rmax (sensitivity). Values are
mean ± SEM of 5–10 mice per group. *p < 0.05 and **p < 0.01 vs. WT
and #p < 0.05 and ##p < 0.01 vs. apoE−/− vehicle (one-way ANOVA); §p < 0.05
and §§p < 0.01 vs. respective control without blockade (two-way ANOVA).
Figure 1 Effect of sildenafil treatment on the endothelial
function of apoE−/− mice. (A) Acetylcholine (ACh)-induced
endothelium-dependent relaxation in aortic rings, comparing
untreated apoE−/− mice with wild-type (WT) control mice. (B) Effect of
the treatment with sildenafil (40 mg/kg/day for 3 weeks) on
ACh-induced vasodilation in apoE−/− mice compared to untreated
apoE−/− and to WT mice. Values are the means ± SEM. *p < 0.05 vs. WT;
#p < 0.05 vs. untreated apoE−/− (two-way ANOVA).
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otic plaque deposition (21.3 ± 5.0, p < 0.05; Figure 4A).
DHE staining revealed an increased oxidative stress in
the aortas from untreated atherosclerotic apoE−/− ani-
mals (3.5 ± 0.4, p < 0.05) compared to the WT group
(2.30 ± 0.1), and treatment with sildenafil reduced the
oxidative stress in aortas from apoE−/− mice (2.4 ± 0.2,
p < 0.05 vs. untreated apoE−/− mice; Figure 4B).
Discussion
This work showed for the first time that chronic inhibition
of PDE5 with sildenafil restored endothelial function in
the aorta of apoE−/− mice. In addition, sildenafil treatment
reduced the atherosclerotic plaque deposition in this large
vessel without affecting the plasma cholesterol levels. The
amelioration of endothelial function and delayed progres-
sion of atherosclerosis that was observed, were mainly
regulated through improving the basal NO pathway acti-
vation and decreasing ROS production.
As expected, the apoE−/− mice showed higher plasma
cholesterol than the WT animals [17-20], exhibiting ap-
proximately a 14-fold increase in total cholesterol, as re-
cently reviewed [4]. Interestingly, sildenafil did not change
the plasma lipid profile in the treated animals, which was
consistent with similar results found elsewhere [21], al-
though it improved the endothelial function. In recent
years, there has been a significant improvement in the de-
velopment of new therapeutics that target cardiovascular
risk factors other than hypercholesterolemia [22]. Similar
to the results in our present study, a class of statins has
been shown to have pleiotropic effects with atheroprotec-
tive properties that were independent of cholesterol and
were mediated by inhibition of isoprenoids [23]. Hence,
Figure 2 Participation of nitric oxide in ACh-induced vasodilation. Concentration-response curves show acetylcholine (ACh)-induced
endothelium-dependent relaxation in aortic rings under the blockade of nitric oxide synthase with L-NAME in wild-type (WT) mice (A), untreated
apoE−/− mice (B) and sildenafil-treated apoE−/− mice (C). Bar graph (D) shows the difference in the area under the curve (AUC) of the response of
aortic rings to ACh with and without L-NAME. A decreased difference in the AUC indicates an impaired response to ACh. Values are the means ±
SEM. **p < 0.01 vs. without L-NAME (A, B and C: two-way ANOVA); **p < 0.01 vs. WT and ##p < 0.01 vs. untreated apoE−/− (D: one-way ANOVA).
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may offer a new perspective for the use of PDE5 inhibitors
in ameliorating endothelial dysfunction and reducing
atherosclerosis.
It has been postulated that the major cause of endothelial
dysfunction observed in apoE−/− mice is the reduction in
the NO pathway, including the increased inactivation of
this species by ROS [4,24]. NO is a multifunctional
molecule, exerting several potentially anti-atherosclerotic
effects, such as antioxidant, anti-inflammatory, anti-platelet
and vasodilator [4,25]. Because the atherosclerotic disease
is initiated by an endothelial dysfunction, novel therapeutics
that potentiate or mimic the increase in NO bioavailability
should also be considered. Sildenafil appears to be a prom-
ising alternative as it inhibits the degradation of cGMP, the
second messenger of NO [4,6,26]. The potential advantageof a therapeutic approach based on inhibition of PDE5 is
that, unlike strategies that attempt to increase NO levels
(e.g., substrates, co-factors, antioxidants) [27], this one
avoids risks associated with excessive NO. At high concen-
trations, NO is a cytotoxic free radical that increases oxida-
tive stress independent of activation of guanylyl cyclase,
thereby contributing to the development of atherosclerosis
through overproduction of peroxynitrite (ONOO-) [28,29].
In the present study, we observed marked endothelial dys-
function in the aorta of apoE−/− mice, as shown before by
others in conductance and resistance vessels [24,25,30,31].
We found that this endothelial dysfunction is related to
reduced participation of NO in the vasodilator response to
ACh, as demonstrated by a reduced area under the ACh
concentration-response curve when blocked with L-NAME;
this was in accordance with previous results [25]. It has
Figure 3 Participation of reactive oxygen species. Data show the effect of the blockade of NADPH oxidase activity with apocynin on the
cumulative concentration–response curve to acetylcholine (ACh) in untreated and treated apoE−/− mice and wild-type (WT) control mice. Values
are mean ± SEM. **p < 0.01 vs. apoE−/− without blockage (one-way ANOVA).
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tivity of endothelial NO synthase (eNOS), even if the ex-
pression of the enzyme is normal [24,32]. Furthermore,
some studies have evaluated the hypothesis that the vascu-
lar dysfunction in apoE−/− mice may be dependent not
only on the reduced bioavailability of NO but also on the
altered responsiveness of vascular smooth muscle cells
(VSMCs) to NO. We did not observe differences in so-
dium nitroprusside responses between WT and untreatedFigure 4 Effect of sildenafil treatment on plaque deposition and oxid
plaque deposition in untreated and treated apoE−/− mice compared to wil
sections of each group of animals. Scale bar 500 μm. (B) Bar graph showin
units) comparing the 3 groups of animals. Photomicrographs above the gr
Scale bar 100 μm. *p < 0.05 and **p < 0.01 untreated apoE−/− vs. WT; #p < 0apoE−/− mice (data not shown), demonstrating that the
prejudice of vascular function is not due to a reduction in
the sensitivity of smooth muscle cells to NO; this contra-
dicts what was previously reported in the mesenteric ar-
teriolar bed [33] and in the aorta [34-36].
The efficacy of sildenafil in promoting the vasodilator
response to ACh was demonstrated in diabetic rats [37]
and in a secondhand smoke mouse model [38]; how-
ever, this efficacy has not yet been demonstrated inative stress. (A) Bar graph showing mean ± SEM values (in %) of
d-type (WT) control mice. Photomicrographs are typical aorta cross-
g mean ± SEM values of dihydroethidium (DHE) labeling (in arbitrary
aph are typical aorta cross-sections showing fluorescent DHE labeling.
.05 treated vs. untreated apoE−/− vehicle (one-way ANOVA).
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of our study is that sildenafil treatment restored endo-
thelial function in this murine model of atherosclerosis.
Once sildenafil main mechanism of action is inhibition
of PDE5 in VSMCs, the drug mimics the increase in NO
availability. In addition, recent data have shown that sil-
denafil can increase the expression [39-41] and activity
[28,38] of eNOS, which could explain the amelioration
of endothelial function and the reduction in atheroscler-
otic lesions.
Our data provide evidence that NADPH-derived ROS
production contributes to oxidative stress in apoE−/− ani-
mals, because apocynin ameliorated ACh-induced relaxa-
tions in this group as shown previously [42]. The novelty of
the present study is that sildenafil treatment restores endo-
thelial function in apoE−/− mice by a reduction in oxidative
stress. It has been shown that increased cGMP can inhibit
NADPH oxidase expression/activity, thereby reducing •O2
-
production, and consequently restoring NO bioavailability.
This antioxidative effect of sildenafil may constitute an add-
itional mechanism for the augmentation of NO-mediated
relaxation [26]. These results on the oxidative stress, as
assessed by a vascular reactivity study, are in accordance
with the in situ observations using frozen sections labeled
with DHE. In accordance with others [24,43,44], we
observed that apoE−/− mice show increased DHE staining,
which represents increased •O2
- production. Our finding is
in agreement with another study, which demonstrated a re-
duction in nitrotyrosine immunostaining (a marker of local
oxidative stress, produced by the interaction of ONOO-
with tyrosine residues in peptides) in ischemic muscles of
apoE−/− animals treated with sildenafil [21].
It has been postulated that atherogenesis is initiated with
an endothelial dysfunction, in response to an injury to the
endothelium caused by risk factors such as dyslipidemia
[1,4]. Thus, interventions that restore endothelial function
can potentially reduce atherosclerotic plaque deposition.
We observed that sildenafil treatment, in addition to ameli-
oration of endothelial function in hypercholesterolemic
apoE−/− mice, is capable of reducing atherosclerosis in the
aorta of treated animals by approximately 40%. Atheroscler-
osis is considered an inflammatory disease, in which the
migration of leucocytes through the endothelial wall is a
crucial event. Circulating monocytes, attracted by chemoat-
tractants that are released by activated endothelial cells, ad-
here to the vessel wall by interacting with E-selectin,
vascular cell adhesion molecule (VCAM-1) and intercellu-
lar adhesion molecule (ICAM-1). This initiates a process of
phagocytosis of modified LDL and foam cell formation
[45]. Sildenafil can reduce atherosclerosis by interfering
with this inflammatory cascade [11] by preventing oxida-
tion of LDL, in addition to improving the endothelial func-
tion. A recent report has shown that a dose of sildenafil
similar to that used in our study increases the number ofbone marrow-derived endothelial progenitor cells in
hypercholesterolemic apoE−/− mice [21]. These cells may
be involved in the reduction of oxidative stress and apop-
tosis through cell therapy, as observed by our group re-
cently [43,44], and this finding may offer new insight into
similar effective therapies.
In conclusion, we are the first to show that chronic silde-
nafil treatment restores endothelial function and reduces
oxidative stress in a murine atherosclerotic model based
on a reduction in plaque deposition in these mice, inde-
pendent of changes in the lipid profile. This study confirms
that sildenafil is a promising novel pharmacologic strategy
to treat atherosclerosis, although further studies are neces-
sary to confirm the safety of this pharmacological approach
in atherosclerotic patients.
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